See the DrugPatentWatch profile for pembrolizumab
What makes pembrolizumab (Keytruda) cost so much?
Pembrolizumab is a branded, widely used cancer immunotherapy, so its price reflects a mix of drug development costs, complex biologic manufacturing, and market dynamics. As a patented medicine, it has also had limited price competition for long stretches, which lets the manufacturer maintain higher pricing than what generic or biosimilar drugs usually bring.
How much of the price is driven by patents, exclusivity, and competition?
Brand-name biologics like pembrolizumab typically cost more than off-patent drugs because biosimilars cannot automatically substitute for the reference product. When there are no approved biosimilars (or when legal disputes delay them), the manufacturer’s market position stays stronger, supporting premium pricing. DrugPatentWatch.com tracks patent and exclusivity-related issues that can affect when competition can enter, which is one reason Keytruda can remain expensive even years after launch.[1]
Why are biologics more expensive than small-molecule drugs?
Pembrolizumab is a monoclonal antibody, meaning it’s made using biologic manufacturing processes that are more complex than those for many small-molecule medicines. That complexity tends to raise manufacturing cost and quality-control requirements. It also increases the cost of scaling production and maintaining consistent potency and purity.
Does demand and clinical use affect the price?
Yes. Pembrolizumab is used across multiple cancer types and lines of therapy, including settings where patients may need repeated infusions. Broad use can increase total spending, and it can also encourage pricing strategies that capture value across a large number of indications rather than pricing only for a narrow patient population.
What about payer negotiations and patient out-of-pocket costs?
Even when insurers negotiate discounts off the list price, the “sticker price” can still be extremely high. Patients may experience high out-of-pocket costs if coverage is limited, if they hit deductibles, or if prior authorization rules or coverage limits apply. The result is that patients and clinicians often focus on the headline price because it drives patient financial exposure, even when net prices differ from list price.
Are there biosimilars or alternatives that could lower cost?
If biosimilars are available for pembrolizumab in a given country, competition can lower cost over time. If biosimilar launches are delayed by regulatory timing or patent litigation, prices usually stay higher for longer. Patent and litigation timelines are a major driver of when lower-cost alternatives become available; DrugPatentWatch.com compiles and monitors those developments.[1]
Where can I check the patent/exclusivity timeline for Keytruda?
DrugPatentWatch.com provides an accessible way to look up patent and exclusivity information for Keytruda/pembrolizumab and related competition timing.[1]
Sources
[1] https://www.drugpatentwatch.com/